

MEDI-CAPS LIMITED

Regd. Office and works:

Mhow - Neemuch Road, Sector 1, CIN: L70100MP1983PLC002231
Pithampur - 454775, Dist. Dhar
Madhya Pradesh, India

Ph:- 07292-256205

Fax:- 0731-4041435

E mail:- investors@medicaps.com

Website:- www.medicaps.com

MCL/SE/2021-2022

Date: 10th February, 2022

Online filing at: www.listing.bseindia.com

To,
The General Manager
DCS-CRD
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street Fort, Mumbai – 400001 (M.H.)

Subject: Submission of the Standalone and Consolidated Unaudited Financial Results for the Quarter and Nine Months ended on 31st December, 2021 as per Regulation 33 of SEBI (LODR) Regulations, 2015.

Ref: MEDI-CAPS LIMITED (BSE Scrip Code: 523144, ISIN: INE442D01010)

Dear Sir/Madam,

This is in Continuation of our letter no. MCL/BM/SE/2021-2022 dated 2nd February, 2021 regarding information of Board Meeting for consideration and approval of Standalone as well as Consolidated Un-Audited Financial Results for the Quarter and Nine months ended on 31st December, 2021.

In compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to submit the Un-audited Standalone and Consolidated Financial Results for the quarter and nine months ended 31st December, 2021 duly approved by the Board at its meeting held today i.e.10th February, 2022 along with Limited Review Report given by the Statutory Auditors of the Company, as required under the above said Regulations.

Further, copy of Un-Audited Financial Statements shall also be submitted in XBRL mode within 24 hours from the conclusion of Board Meeting.


The aforesaid results will be uploaded on the Company's website www.medicaps.com and on the website of the Stock Exchange at www.bseindia.com. Further the extracts of aforesaid results will be published in Hindi (vernacular) and widely circulated English Newspaper.

You are requested to please take on record the aforesaid Results for your records and reference.

Thanking You,

Yours Faithfully,

FOR, MEDI-CAPS LIMITED



ALOK K GARG
MANAGING DIRECTOR

DIN: 00274321



Encl.: Unaudited Standalone and Consolidated Financial Results along with limited review report for quarter and nine months ended 31st December, 2021;

*Corporate Office: 201, Pushpratna Paradise 9/5 New Palasiya,
Opposite UCO Bank Indore (M.P.) 452001
Contact No: 0731-4028148*

RAWKA & ASSOCIATES

CHARTERED ACCOUNTANTS

412, Arcade Silver 56, 1, New Palasia, Indore - 1

☎ Off. : 2541132, Mobile : 9039080380

E-mail : rawkaassociates@gmail.com, cprawka@gmail.com

Independent Auditors' Review Report on Standalone Unaudited Quarterly and Year to date Financial Results of Medi-Caps Limited ('the Company') pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,

The Board of Directors of
Medi-Caps Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results ("the Statement") of MEDI-CAPS LIMITED ("the Company") for the quarter ended December 31st, 2021 and for the period from April 01, 2021 to December 31st, 2021 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'), including relevant circulars issued by the SEBI from time to time. The Statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors. Our responsibility is to issue a report on the Statement based on our review of the Statement, which has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), specified under Section 133 of the Companies Act, 2013 read with relevant rules issued there under, and other accounting principles generally accepted in India and in Compliance with Regulation 33 of the Listing Regulations.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable Indian accounting standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognised accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.
4. On 21st November , 2019 Company announce to permanently discontinue the Company's operations related to production/manufacturing of hard gelatin capsule shell in the plant situated at Mhow-Neemuch Road, Sector 1, Pithampur – 454775, Distt. Dhar. The discontinuation is consistent with the company's long term strategy to focus its activities in the areas of real estate business and to divest unrelated activities. Accordingly loss for the quarter ended December 31, 2021 is from discontinue operations of Rs. 3.22 Lakhs .

Place: Indore


Date: 10/02/2022

UDIN: 22429040ABEBNF1422

For: Rawka & Associates

(Chartered Accountants)

FRN 021606C



Venus Rawka

(Partner)

M. No. 429040

Regd. Office and works:
Mhow - Neemuch Road, Sector 1,
Pithampur - 454775, Dist. Dhar
Madhya Pradesh, India

CIN: L70100MP1983PLC002231

Ph:- 07292-256205
Fax:- 0731-4041435
E mail:- investors@medicaps.com
Web site:- www.medicaps.com

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2021


(Amount in Lakhs except EPS)

S.N.	Particulars	Quarter Ended			Nine Months		Previous Year Ended on 31.03.2021
		3 Month ended On 31.12.2021	Previous 3 Month ended On 30.09.2021	Corresponding 3 Month ended On 31.12.2020	Year to date figures for current period ended 31.12.2021	Year to date figures For the Previous Period ended 31.12.2020	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	
I	Revenue from operations	0.00	0.02	0.00	0.02	0.00	0.00
II	Other Income	43.50	1.64	0.00	46.41	0.00	0.00
III	Total Income (I+II)	43.50	1.66	0.00	46.43	0.00	0.00
IV	Expenses						
	(A) Cost of Material Consumed	0.00	0.00	0.00	0.00	0.00	0.00
	(B) Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	(C) Change in inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	(D) Employee benefits expenses	31.68	4.74	0.00	40.55	0.00	0.00
	(E) Depreciation & amortization expenses	5.44	5.43	0.00	16.31	0.00	0.00
	(F) Finance Cost	0.00	0.00	0.00	0.00	0.00	0.00
	(G) Power Cost	0.00	0.00	0.00	0.00	0.00	0.00
	(H) Freight expenses	0.00	0.00	0.00	0.00	0.00	0.00
	(I) Other Expenses	3.46	2.37	0.00	9.85	0.00	0.00
	Total Expenses	40.58	12.54	0.00	66.71	0.00	0.00
V	Profit/(Loss) before exceptional items & Tax (III-IV)	2.92	(10.89)	0.00	(20.28)	0.00	0.00
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
VII	Profit/Loss before tax (V-VI)	2.92	(10.89)	0.00	(20.28)	0.00	0.00
VIII	Tax Expenses						
	Current Tax	0.00	0.00	0.00	0.00	0.00	0.00
	Deferred Tax	0.00	0.00	0.00	0.00	0.00	(0.51)
IX	Profit/Loss for the period (from continuing operation)(VII-VIII)	2.92	(10.89)	0.00	(20.28)	0.00	0.51
X	Profit/(Loss) from discontinued operations	(3.22)	(4.03)	(8.91)	(0.42)	(41.50)	(11.59)
XI	Tax expenses of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
XII	Profit/(Loss) from discontinued operations (after tax) (X-XI)	(3.22)	(4.03)	(8.91)	(0.42)	(41.50)	(11.59)
XIII	Share of profit (loss) of associates and joint ventures accounted for using equity method	0.00	0.00	0.00	0.00	0.00	0.00


XIV	Profit/(Loss) for the period	(0.30)	(14.92)	(8.91)	(20.70)	(41.50)	(11.08)
XV	Other Comprehensive Income						
	A.(i) Item that will not be reclassified to profit & Loss	(35.94)	39.10	48.13	29.25	105.59	123.47
	(ii) Income tax relating to items that will not be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
	B.(i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
XVI	Total Comprehensive Income for the period comprising Profit(Loss) and other comprehensive income for the period	(36.24)	24.18	39.22	8.55	64.09	112.39
XVII	Total profit or loss attributable to						
	Profit or Loss attributable to owners of parent	0.00	0.00	0.00	0.00	0.00	0.00
	Profit or loss attributable to non-controlling interests	0.00	0.00	0.00	0.00	0.00	0.00
XVIII	Total Comprehensive income for the period attributable to						
	Comprehensive income for the period attributable to owners of parent	0.00	0.00	0.00	0.00	0.00	0.00
	Comprehensive income for the period attributable to non-controlling interests	0.00	0.00	0.00	0.00	0.00	0.00
XIX	Paid-up equity share capital @ Rs. 10/- each	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00
XX	Reserve excluding Revaluation Reserves as per balance sheet of previous year	0.00	0.00	0.00	0.00	0.00	4849.91
XXI	Earnings Per Equity Share (for continuing operation)						
	a) BASIC	0.02	(0.09)	0.39	(0.16)	0.85	0.99
	b) DILUTED	0.02	(0.09)	0.39	(0.16)	0.85	0.99
XXII	Earnings Per Equity Share (for discontinued operation)						
	a) BASIC	(0.03)	(0.03)	(0.07)	0.00	(0.33)	(0.09)
	b) DILUTED	(0.03)	(0.03)	(0.07)	0.00	(0.33)	(0.09)
XXIII	Earnings Per Equity Share (for continuing & discontinued operation)						
	a) BASIC	(0.01)	(0.12)	0.32	(0.16)	0.52	0.90
	b) DILUTED	(0.01)	(0.12)	0.32	(0.16)	0.52	0.90

DATE: 10.02.2022
PLACE: INDORE

For, MEDI-CAPS LIMITED



ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321




Independent Auditor's Review Report On Consolidated Unaudited Quarterly and year to date Financial Results of Medi-Caps Limited (the Parent Company) Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To

The Board of Directors of
Medi-Caps Limited

1. We have reviewed the accompanying Statement of the Unaudited Consolidated Financial Results ("the Statement") of Medi-Caps Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit after tax and total comprehensive profit for the quarter ended December 31, 2021 and for the period from April 01, 2021 to December 31, 2021, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations"), including relevant circular issued by the SEBI time to time.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of its wholly owned subsidiary Medgel Private Limited.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of its subsidiary, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. Our conclusion is not modified in respect of this matter.

7. The consolidated unaudited financial results includes the interim financial statements / financial information/ financial results of Medgel Private Limited (wholly owned subsidiary) which also have been reviewed by us and certified by the management, whose interim consolidated financial statements/ financial information/ financial results reflect total revenue of Rs. 1799.68 Lakhs, total net profit after tax of Rs. 204.93 Lakhs and total comprehensive income of Rs. (26.86) Lakhs for the quarter ended December 31, 2021, as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial statements/ financial information/ financial results are not material to the group.

Our Conclusion on the statement is not modified in respect of above matter.

Place: Indore

Date: 10/02/2022

UDIN:22429040ABDYIL5116

For: Rawka & Associates

(Chartered Accountants)

FRN: 021606C



A handwritten signature in black ink, appearing to read "Venus Rawka".

Venus Rawka
(Partner)

M.No. 429040

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2021


(Amount in Lakhs except EPS)

S.N.	Particulars	Quarter Ended			Nine Months		Previous Year Ended on 31.03.2021
		3 Month ended On 31.12.2021	Previous 3 Month ended On 30.09.2021	Corresponding 3 Month ended On 31.12.2020	Year to date figures for current period ended 31.12.2021	Year to date figures For the Previous Period ended 31.12.2020	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	
I	Revenue from operations	1778.30	1731.40	1816.19	5231.75	4519.61	5871.89
II	Other Income	21.38	13.08	11.15	46.83	42.97	58.37
III	Total Income (I+II)	1799.68	1744.48	1827.34	5278.58	4562.58	5930.26
IV	Expenses						
	(A) Cost of Material Consumed	778.86	689.19	938.80	2270.43	2322.20	3107.60
	(B) Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	(C) Change in inventories of finished goods, work-in-progress and stock-in-trade	4.94	24.58	89.01	88.12	(29.15)	(171.32)
	(D) Employee benefits expenses	196.81	191.38	178.40	552.57	482.76	670.99
	(E) Depreciation & amortization expenses	47.34	47.34	37.31	142.02	111.93	152.11
	(F) Finance Cost	0.02	0.00	0.00	0.02	0.00	0.00
	(G) Power Cost	106.00	93.66	50.12	245.62	167.27	256.47
	(H) Freight Expenses	311.93	279.69	22.06	640.36	67.02	161.26
	(I) Other Expenses	145.63	95.93	168.59	480.57	546.96	629.17
	Total Expenses	1591.53	1421.77	1484.29	4419.71	3668.99	4806.28
V	Profit/(Loss) before exceptional items & Tax (III-IV)	208.15	322.71	343.05	858.87	893.59	1123.98
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
VII	Profit/Loss before tax (V-VI)	208.15	322.71	343.05	858.87	893.59	1123.98
VIII	Tax Expenses						
	Current Tax	0.00	0.00	0.00	0.00	0.00	0.00
	Deferred Tax	0.00	0.00	0.00	0.00	0.00	(0.51)
IX	Profit/Loss for the period (from continuing operation)(VII-VIII)	208.15	322.71	343.05	858.87	893.59	1124.49
X	Profit/(Loss) from discontinued operations	(3.22)	(4.03)	(8.91)	(0.42)	(41.50)	(11.59)
XI	Tax expenses of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
XII	Profit/(Loss) from discontinued operations (after tax) (X-XI)	(3.22)	(4.03)	(8.91)	(0.42)	(41.50)	(11.59)
XIII	Share of profit (loss) of associates and joint ventures accounted for using equity method	0.00	0.00	0.00	0.00	0.00	0.00

XIV	Profit/(Loss) for the period	204.93	318.67	334.14	858.45	852.09	1112.90
XV	Other Comprehensive Income						
	A.(i) Item that will not be reclassified to profit & Loss	(26.86)	83.74	96.30	122.21	221.96	262.88
	(ii) Income tax relating to items that will not be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
	B.(i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
XVI	Total Comprehensive Income for the period comprising Profit(Loss) and other comprehensive income for the period	178.07	402.42	430.44	980.66	1074.05	1375.78
XVII	Total profit or loss attributable to						
	Profit or Loss attributable to owners of parent	204.93	318.67	334.14	858.45	852.09	1112.90
	Profit or loss attributable to non-controlling interests	0.00	0.00	0.00	0.00	0.00	0.00
XVIII	Total Comprehensive income for the period attributable to						
	Comprehensive income for the period attributable to owners of parent	178.07	402.42	430.44	980.66	1074.05	1375.78
	Comprehensive income for the period attributable to non-controlling interests	0.00	0.00	0.00	0.00	0.00	0.00
XIX	Paid-up equity share capital @ Rs. 10/- each	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00
XX	Reserve excluding Revaluation Reserves as per balance sheet of previous year	0.00	0.00	0.00	0.00	0.00	9224.24
XXI	Earnings Per Equity Share (for continuing operation)						
	a) BASIC	1.67	2.59	2.75	6.89	8.95	11.13
	b) DILUTED	1.67	2.59	2.75	6.89	8.95	11.13
XXII	Earnings Per Equity Share (for discontinued operation)						
	a) BASIC	(0.03)	(0.03)	(0.07)	0.00	(0.33)	(0.09)
	b) DILUTED	(0.03)	(0.03)	(0.07)	0.00	(0.33)	(0.09)
XXIII	Earnings Per Equity Share (for continuing & discontinued operation)						
	a) BASIC	1.64	2.56	2.68	6.89	8.62	11.04
	b) DILUTED	1.64	2.56	2.68	6.89	8.62	11.04

DATE: 10.02.2022
PLACE: INDORE

For, MEDI-CAPS LIMITED


ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321



MC MEDI-CAPS LIMITED

Regd. Office and works:
Mhow - Neemuch Road, Sector 1,
Pithampur - 454775, Dist. Dhar
Madhya Pradesh, India

CIN: L70100MP1983PLC002231

Ph:- 07292-256205
Fax:- 0731-4041435
E mail:- investors@medicaps.com
Web site:- www.medicaps.com

SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED FOR QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2021

(Amount in Lakhs)

S.N.	Particulars	Quarter Ended			Nine Months Ended		Previous Year ended on 31.03.2021
		3 months ended on 31.12.2021	Previous 3 months ended on 30.09.2021	Corresponding 3 months ended on 31.12.2020	Year to date figures for Current period ended on 31.12.2021	Year to date figures for Previous period ended 31.12.2020	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	
1.	Segment Revenue						
	A) Pharma Division	1756.16	1742.86	1752.73	5232.15	4562.57	5930.26
	B) Real Estate Division	43.52	1.64	0.00	46.43	0.00	0.00
	C) Others	0.00	0.00	0.00	0.00	0.00	0.00
	Gross Turnover	1799.68	1744.48	1752.73	5278.58	4562.57	5930.26
	Less inter segment revenue	0.00	0.00	0.00	0.00	0.00	0.00
	Total Income from Operation	1799.68	1744.48	1752.73	5278.58	4562.57	5930.26
2.	Segment Results						
	A) Pharma Division	205.23	333.59	343.04	879.15	893.59	1123.98
	B) Real Estate Division	2.92	(10.89)	0.00	(20.28)	0.00	0.00
	C) Others	0.00	0.00	0.00	0.00	0.00	0.00
	Total Segment Profit/(Loss) before interest and taxes	208.15	322.71	343.04	858.87	893.59	1123.98
	Finance Cost	0.00	0.00	0.00	0.00	0.00	0.00
	Other un-allocable Expenditure net off Un-allocable income	0.00	0.00	0.00	0.00	0.00	0.00
	Profit/(Loss) before tax	208.15	322.71	343.04	858.87	893.59	1123.98

Corporate Office: 201, Pushpratna Paradise 9/5 New Palasiya,
Opposite UCO Bank Indore (M.P.) 452001
Contact No: 0731-4028148

	Current Tax	0.00	0.00	0.00	0.00	0.00	0.00
	Deferred tax	0.00	0.00	0.00	0.00	0.00	(0.51)
	Profit/(Loss) after tax	208.15	322.71	343.04	858.87	893.59	1124.49
3.	Segment Assets						
	A) Pharma Division	12231.75	12006.04	10936.33	12231.75	10936.33	11381.88
	B) Real Estate Division	181.55	301.47	100.00	181.55	100.00	100.00
	C) Unallocated	0.00	0.00	0.00	0.00	0.00	0.00
	Total Segment Assets	12413.30	12307.51	11036.33	12413.30	11036.33	11481.88
4.	Segment Liabilities (External Liabilities)						
	A) Pharma Division	961.40	933.70	766.83	961.40	766.83	910.64
	B) Real Estate Division	0.00	100.00	100.00	0.00	100.00	100.00
	C) Unallocated	0.00	0.00	0.00	0.00	0.00	0.00
	Total Segment Liabilities	961.40	1033.70	866.83	961.40	866.83	1010.64
5.	Capital Employed						
	A) Pharma Division	11270.35	11072.34	10169.50	11270.35	10169.50	10471.24
	B) Real Estate Division	181.55	201.47	0.00	181.55	0.00	0.00
	C) Unallocated	0.00	0.00	0.00	0.00	0.00	0.00
	Total Capital Employed	11451.90	11273.81	10169.50	11451.90	10169.50	10471.24

DATE: 10.02.2022
PLACE: INDORE



For, MEDI-CAPS LIMITED

(Handwritten Signature)

ALOK K GARG
MANAGING DIRECTOR
DIN:00274321

NOTES:

1. The above unaudited financial results for the Quarter and Nine months ended December 31, 2021 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on February 10, 2022. The above results have been reviewed by statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, who have expressed an unmodified opinion.
2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
3. The above consolidated financial results includes the result of wholly owned subsidiary company i.e. Medgel Private Limited.
4. The Company has two reportable segments for the Consolidated Financial Statements which consists Pharma division and Real Estate division in accordance with Ind AS-108 Operating Segment and same is enclosed with this result.
5. The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary.
6. The aforesaid Un-audited financial Results will be uploaded on the Company's website www.medicaps.com and will also be available on the websites of the Stock exchange i.e. www.bseindia.com for the benefit of shareholders and investors.
7. On 21st Nov., 2019, the company announced to permanently discontinue Company's operations related to production/manufacturing of Hard Gelatin Capsule Shell. The discontinuation is consistent with the Company's long-term strategy to focus its activities in the areas of Real Estate Business and to divest unrelated activities. Accordingly, Loss for the quarter ended December 31, 2021 is from discontinuing operation.
8. The construction of commercial complex in the name and style of Medicaps Business Park at Pithampur is under process and booking shall be started after obtaining approval from Real Estate Regulatory Authority
9. Description of Income & Expenditure of Discontinue operations


(Amount in Lakhs)

	Particulars	3 Month	3 Months	9 Months
		Ended	Ended	Ended
		31.12.2021	30.09.2021	31.12.2021
I	Income from operations	0.00	0.00	0.00
II	Other Income	1.13	0.24	12.49

III	Total income (I+II)	1.13	0.24	12.49
IV	Expenses			
	a) Changes in Inventories of finished goods, & work in progress	0.00	0.00	0.00
	b) Employee benefits expense	0.00	0.00	0.00
	c) Finance Cost	0.00	0.00	0.00
	d) Depreciation expense	2.84	2.84	8.52
	e) Other expenses	1.51	1.43	4.39
	Total Expenses (IV)	4.35	4.27	12.91
V	Net Profit/Loss From Discontinue Operation	-3.22	-4.03	-0.42

DATE : 10.02.2022
PLACE: INDORE

For, MEDI-CAPS LIMITED



ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

